Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing

Experimental and Molecular Pathology

Volumn 99, Issue 2, 2015, Pages 240-244

  Putra, Juan ^a   de Abreu, Francine B ^a   Peterson, Jason D ^a   Pipas, J Marc ^b   Mody, Kabir ^b   Amos, Christopher I ^b   Tsongalis, Gregory J ^a   Suriawinata, Arief A ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Extrahepatic cholangiocarcinoma; Intrahepatic cholangiocarcinoma; Next generation sequencing; Somatic mutations; Targeted therapy

Indexed keywords

B RAF KINASE; ISOCITRATE DEHYDROGENASE 1; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT DISEASE; BRAF GENE; CLINICAL ARTICLE; EXTRAHEPATIC CHOLANGIOCARCINOMA; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IDH1 GENE; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; NRAS GENE; ONCOGENE; ONCOGENE K RAS; QUALITY CONTROL; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; VERY ELDERLY; BILE DUCT TUMOR; EXTRAHEPATIC BILE DUCT; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; INTRAHEPATIC BILE DUCT; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; BIOMARKERS, TUMOR; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84938079607     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.07.005     Document Type: Article

References (25)

1. Borger D.R., Tanabe K.K., Fan K.C., Lopez H.U., Fantin V.R., Straley K.S., et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012, 17:72-79.
2. Cardinale V., Semeraro R., Torrice A., Gatto M., Napoli C., Bragazzi M.C., et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J. Gastrointest. Oncol. 2010, 2:407-416.
3. Churi C.R., Shroff R., Wang Y., Rashid A., Kang H.C., Weatherly J., et al. Mutation, profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 2014, 9:e115383.
4. El-khoueiry A.B., Rankin C.J., Ben-Josef E., Lenz H.J., Gold P.J., Hamilton R.D., et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest. New Drugs 2012, 30:1646-1651.
5. (Last date accessed: 02/17/15). http://www.cancer.org/acs/groups/cid/documents/webcontent/003084-pdf.pdf.
6. Jang S., Chun S.M., Hong S.M., Sung C.O., Park H., Kang H.J., et al. High throughput molecular profiling reveals differential mutation patterns n intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. Mod. Pathol. 2014, 27:731-739.
7. Jiao Y., Pawlik T.M., Anders R.A., Selaru F.M., Streppel M.M., Lucas D.J., et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 2013, 45:1470-1473.
8. Khan S.A., Thomas H.C., Toledano M.B., Cox I.J., Taylor-Robinson S.D. P53 mutations in human cholangiocarcinoma: a review. Liver Int. 2005, 25:704-716.
9. Khan S.A., Emadossadaty S., Ladep N.G., Thomas H.C., Elliott P., Taylor-Robinson S.D., Toledano M.B., et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J. Hepatol. 2012, 56:848-854.
10. Kipp B.R., Voss J.S., Kerr S.E., Barr Fritcher E.G., Graham R.P., Zhang L., et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum. Pathol. 2012, 43:1552-1558.
11. Miller G., Socci N.D., Dhall D., D'Angelica M., DeMatteo R.P., Allen P.J., et al. Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J. Exp. Clin. Cancer Res. 2009, 28:62.
12. Reitman Z.J., Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 2010, 102:932-941.
13. Rizvi S., Borad M.J., Patel T., Gores G.J. Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin. Liver Dis. 2014, 34:456-464.
14. Rohle D., Popovici-Muller J., Palaskas N., Turcan S., Grommes C., Campos C., et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340:626-630.
15. Ross J.S., Wang K., Gay L., Al-Rohil R., Rand J.V., Jones D.M., et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014, 19:235-242.
16. Sempoux C., Jibara G., Ward S.C., Fan C., Qin L., Roayaie S., et al. Intrahepatic cholangiocarcinoma: new insights in pathology. Semin. Liver Dis. 2011, 31:49-60.
17. Sia D., Hoshida Y., Villanueva A., Roayaie S., Ferrer J., Tabak B., et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013, 144:829-840.
18. Sia D., Losic B., Moeini A., Cabellos L., Hao K., Revill K., et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat. Commun. 2015, 6:6087.
19. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003, 52:706-712.
20. Tsongalis G.J., Peterson J.D., De Abreu F.B., Tunkey C.D., Gallagher T.L., Strausbaugh L.D., et al. Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin. Chem. Lab. Med. 2014, 52:707-714.
21. Turaga K.K., Tsai S., Wiebe L.A., Evans D.B., Gamblin T.C. Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma. Ann. Surg. Oncol. 2013, 20:1230-1239.
22. Wang P., Dong Q., Zhang W., Kuan P.F., Liu Y., Jeck W.R., et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013, 32:3091-3100.
23. Ward P.S., Patel J., Wise D.R., Abdel-Wahab O., Bennett B.D., Coller H.A., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
24. Yoshikawa D., Ojima H., Iwasaki M., Hiraoka N., Kosuge T., Kasai S., et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br. J. Cancer 2008, 98:418-425.
25. Zhu A.X., Borger D.R., Kim Y., Cosgrove D., Ejaz A., Alexandrescu S., et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann. Surg. Oncol. 2014, 21:3827-3834.